You are here: Industry Insights > 7HP349

News List

7 Hills Pharma Receives NCI Grant for Immunostimulant Trials americanpharmaceuticalreview
September 23, 2020
7 Hills Pharma has been awarded a two-year, $2 million Small Business Innovation Research (SBIR) grant from the National Cancer Institute (NCI) of the U.S. National Institutes of Health.
7 Hills Pharma Announces Positive Data with Oral Immunostimulant to Improve Effectiveness of COVID-19 Vaccines americanpharmaceuticalreview
July 16, 2020
7 Hills Pharma announced preclinical studies reveal 7HP349, an oral integrin activator that promotes cell adhesion, significantly increases IgG binding antibodies with a vaccine targeting SARS-CoV-2 (COV2), the virus that causes COVID-19.
7 Hills Announces Positive Data On 7HP349 contractpharma
July 08, 2020
Studies show the small molecule adjuvant increases IgG binding antibody responses.
7 Hills Pharma Announces FDA Clearance of IND Application for Immune Stimulant americanpharmaceuticalreview
April 15, 2020
7 Hills Pharma announced the U.S. Food and Drug Administration (FDA) has cleared the company’s investigational new drug (IND) application for 7HP349.